Novel Therapeutic Approaches and Targets for the Treatment of Atopic Dermatitis.

Atopic Dermatitis is one of the most common inflammatory skin diseases, with an estimated prevalence of 2.1-4.9% in adults. Recently, advances in Atopic Dermatitis understanding have highlighted the role of inappropriate Th2 cell activation as principally involved in its pathogenesis. Other immune pathways seem to play a key role in the complex Atopic Dermatitis pathophysiology. The anti-IL-4/IL-13 was the first monoclonal antibody approved for the treatment of moderate to severe atopic dermatitis in adult patients whose disease is resistant to other therapies. Following its interesting results in terms of efficacy and safety, new therapies are in development. Monoclonal antibodies targeting IL-5, IL-13, IL-17, IL-22, IL-23, IL-31 and TSLP are currently under investigation on patients with moderate to severe Atopic Dermatitis patients. Moreover, small molecules like anti-PDE4 and JAK inhibitors may also represent other treatment possibilities. In this section, we present data available on the efficacy and safety of newer molecules for the treatment of Atopic Dermatitis. The extreme clinical heterogeneity and the chronic progression of Atopic Dermatitis need for newer, safer and more effective treatments, able to control the disease and to improve the quality of life of affected patients. Dupilumab, and the other monoclonal antibodies and small molecules currently under investigation aim to improve the clinical management of Atopic Dermatitis.

Pescitelli L ，Rosi E ，Ricceri F ，Pimpinelli N ，Prignano F ... -  《-》

IL-13 antagonists in the treatment of atopic dermatitis.

Tubau C ，Puig L 《-》

Current and Emerging Biologics for Atopic Dermatitis.

Atopic dermatitis (AD) is a common chronic pruritic inflammatory skin disease that affects all ages and is recognized as a global health problem. Pathophysiology is complex with skin barrier abnormalities, immune dysregulation, and microbial dysbiosis all implicated. Markers of immune and inflammatory activation in the circulation provide a rationale for systemic therapy. Type 2 immune polarization is central, though other cytokine pathways including Th22 and Th17/IL-23 have been described, suggesting additional therapeutic targets in a subset of patients. Dupilumab and tralokinumab are monoclonal antibodies currently approved for moderate-to-severe AD with lebrikizumab and nemolizumab in late stages of development.

Nevid M ，Boguniewicz M 《-》

Novel systemic drugs in treatment of atopic dermatitis: results from phase II and phase III studies published in 2017/2018.

Werfel T 《-》

Dupilumab, A Monoclonal Antibody for Atopic Dermatitis: A Review of Current Literature.

Blakely K ，Gooderham M ，Papp K 《-》